{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:14:07Z","timestamp":1789110847953,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII\u2010equivalent activity (FVIIIeq) of emicizumab remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To estimate FVIIIeq of emicizumab using global assays of haemostasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients\/Methods<\/jats:title>\n                    <jats:p>We sampled plasma from (1) PWHA of all severities and therapeutic regimens and (2) persons with severe haemophilia A on emicizumab. Thrombin generation assay (TGA) and clot formation and lysis assay (CLA) were measured by commercially available (Technothrombin, Technoclone) and turbidimetric assays, respectively. FVIII was measured by a chromogenic (CSA) and emicizumab by a modified one\u2010stage assay (OSA). Using principal components (PC) or individual parameters as dependent and independent variables in linear regression with (1) FVIII and (2) emicizumab levels, respectively, we estimated FVIIIeq (95% CI) of emicizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We collected 253 samples from 110 PWHA and 41 samples from nine individuals on emicizumab prophylaxis. TGA parameters of emicizumab\u2010treated subjects clustered distinctly, with no correlation amongst samples with only endo\u2010\/exogenous FVIII. Consequently, FVIIIeq varied substantially between parameters: Using individual TGA parameters, endogenous thrombin potential (ETP) and thrombin peak resulted in conversion factors of 0.85 (0.60\u20131.24) and 0.25 (0.15\u20130.37) IU\/dL FVIIIeq per \u00b5g\/mL emicizumab, respectively. CLA parameters showed broader overlap, with an FVIIIeq estimate of 0.82 (0.44\u20131.38).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Distinct clustering of emicizumab and FVIII samples in TGA leads to conflicting FVIIIeq estimates between parameters, highlighting systematic limitations and questioning their clinical usefulness. A, possibly conservative, FVIIIeq conversion factor estimate as determined by the thrombin peak could range from 0.15 to 0.37.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70085","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T16:59:56Z","timestamp":1752771596000},"page":"1092-1102","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Estimating the Factor VIII\u2010Equivalent Activity of Emicizumab Using Global Assays of Haemostasis"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8845-081X","authenticated-orcid":false,"given":"Daniel","family":"Kraemmer","sequence":"first","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Rejt\u0151","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Heinze","sequence":"additional","affiliation":[{"name":"Institute of Clinical Biometrics, Center for Medical Data Science Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Quehenberger","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-9896","authenticated-orcid":false,"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"K\u00f6nigsbr\u00fcgge","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00278-x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03962.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.05.026"},{"key":"e_1_2_10_7_1","first-page":"815","article-title":"Mortality Rates, Life Expectancy, and Causes of Death in People With Hemophilia A or B in the United Kingdom Who Were Not Infected With HIV","volume":"110","author":"Darby S. C.","year":"2007","journal-title":"Blood American Society of Hematology"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_10_10_1","first-page":"30","article-title":"Haven 2: Emicizumab Prophylaxis for Children With Haemophilia A With FVIII Inhibitors","volume":"185","author":"Young G.","year":"2019","journal-title":"British Journal of Haematology"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801662"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1688687"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000849"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14430"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1692427"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2023.01.007"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14529"},{"key":"e_1_2_10_21_1","volume-title":"R Foundation for Statistical Computing","author":"R Core Team","year":"2022"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12474"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004334"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03276-7"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006684"},{"key":"e_1_2_10_27_1","first-page":"45","article-title":"Pharmacokinetics and Biomarkers in Persons With Haemophilia a (PwHA) Receiving Emicizumab Every 2 or 4 Weeks","volume":"25","author":"Kiialainen A.","year":"2019","journal-title":"Haemophilia"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1717114"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.03.022"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1769788"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14359"},{"key":"e_1_2_10_32_1","first-page":"336","article-title":"Emicizumab Improves Factor X Activation and Thrombin Generation Similar to Mild Hemophilia in Persons With Hemophilia A and Inhibitors","volume":"3","author":"Manco\u2010Johnson M.","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010331"},{"issue":"2","key":"e_1_2_10_34_1","first-page":"1","article-title":"FVIII In Vitro Bioequivalence of Mim8 Haemostatic Effect by Thrombin Generation Assays [OC 50.5]","volume":"8","author":"Lund J.","year":"2024","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13134"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15640"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13961"},{"key":"e_1_2_10_38_1","first-page":"1836","article-title":"Differences in Venous Clot Structures Between Hemophilic Mice Treated With Emicizumab Versus Factor VIII or Factor VIIIFc","volume":"109","author":"Sefiane T.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286982"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02698-8"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02539.x"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1619052"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12381"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70085","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T20:55:19Z","timestamp":1773003319000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/hae.70085"],"URL":"https:\/\/doi.org\/10.1111\/hae.70085","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"2025-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}